Indivior PLC (LON:INDV) had its price target raised by Morgan Stanley from GBX 320 ($4.21) to GBX 410 ($5.39) in a research note published on Thursday morning. Morgan Stanley currently has an equal weight rating on the specialty pharmaceutical company’s stock.

A number of other research analysts have also recently issued reports on the company. Jefferies Group LLC lifted their price objective on Indivior PLC from GBX 358 ($4.71) to GBX 472 ($6.21) and gave the company a buy rating in a report on Thursday. Citigroup Inc. raised Indivior PLC to a buy rating and lifted their price target for the company from GBX 280 ($3.68) to GBX 490 ($6.44) in a report on Wednesday. Numis Securities Ltd reaffirmed a buy rating and issued a GBX 500 ($6.58) price target on shares of Indivior PLC in a report on Monday, October 30th. Stifel Nicolaus reaffirmed a buy rating and issued a GBX 400 ($5.26) price target on shares of Indivior PLC in a report on Friday, September 15th. Finally, Royal Bank Of Canada reaffirmed an outperform rating and issued a GBX 470 ($6.18) price target on shares of Indivior PLC in a report on Thursday, August 3rd. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The stock has an average rating of Buy and an average target price of GBX 448.14 ($5.89).

Shares of Indivior PLC (LON:INDV) traded down GBX 4.50 ($0.06) during midday trading on Thursday, hitting GBX 378.60 ($4.98). The company’s stock had a trading volume of 2,112,187 shares, compared to its average volume of 2,840,000. Indivior PLC has a 12 month low of GBX 246.50 ($3.24) and a 12 month high of GBX 421.50 ($5.54).

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Watch List News and is owned by of Watch List News. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at

Indivior PLC Company Profile

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.

Analyst Recommendations for Indivior PLC (LON:INDV)

Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.